Suppressed Wound Healing In a Patient with Rheumatoid Arthritis Taking Leflunomide (Arava)

Tweet

D Miller Wise, MD

Fall 2011 - Volume 15 Number 4

http://dx.doi.org/10.7812/TPP/11-044

Abstract

Although patients with rheumatoid arthritis taking disease-modifying antirheumatic drugs (DMARDs) are monitored for various medication adverse events, DMARDs, and leflunomide in particular, have effects that are not observed clinically, specifically adverse effects on wound healing.

Introduction

Patients with rheumatoid arthritis (RA), while taking newer disease-modifying antirheumatic drugs (DMARDs), are examined clinically for decreases in morning stiffness, in joint swelling or tenderness, and for medication adverse effects. Unfortunately, DMARDs have adverse effects not seen clinically. I believe that DMARDs, and leflunomide (LEF) in particular, have adverse effects on wound healing.¹ When the patients with RA do not heal after surgery, a DMARD may be the cause. I report here the case of a patient with RA whose wound did not heal for three years, most likely because of LEF. Further study is needed to determine safe use of DMARDs for these patients when they undergo surgery.²

Case Report

A white woman, age 60 years, with RA of the back, shoulders, knees, and hands had obtained no benefit from nonsteroidal anti-inflammatory drugs, sulfasalazine (Azulfidine), methotrexate, prednisone, or hydroxychloroquine (Plaquenil), alone or combined. LEF (Arava) provided improved control of her RA.

A diagnosis of a large ovarian cyst in our patient led to a total abdominal hysterectomy by Pfannenstiel incision. The fascial repair would not heal, so a vacuum-assisted closure device was applied to her wound. However, an incisional hernia developed. During a period of 2 years, the hernia grew to 30 cm in diameter, and the fascia and skin wound would not heal, despite drainage procedures, mesh repair, mesh removal with repeated fascial repairs, or intermittent use of the vacuum device (Figure 1).

During review of medications and a search of the literature on LEF, I found reports of patients taking LEF for RA or autoimmune vasculitis who developed leg ulcers, poor wound healing, and complications^3–59 (Table 1). Furthermore, some patients' ulcers healed after LEF washout with cholestyramine.⁴ A hypothesis grew: LEF is suppressing our patient's healing; stop it, wash it out, and she may heal.⁴

Data for serum LEF level were not available locally; distant results take time. It seemed imprudent to wait for data on serum level after repeated washout procedures and after the patient had lived with an enlarging hernia for more than two years. The patient and I agreed that the benefits of washouts outweighed the risks of waiting to confirm serum LEF level. I did two washouts of LEF with oral cholestyramine, each during a one-week period as described in the literature, and I scheduled a hernia repair with abdominal-wall reconstruction.^4-6

Within 10 days of the first washout, empiric evidence of healing appeared: The lower wound bled for the first time in 2 years, the granulation tissue was redder and thicker, and the lower epithelial wound border advanced 1 cm.

At surgery, the chronic wound was peeled off the bowel, and then the hernia was reduced with no enterotomies. Poorly vascularized abdominal skin was removed. We placed a single-layer underlay of AlloDerm acellular dermal matrix, with the reticular dermal side up against the peritoneum and musculofascial layer.^47–50 The AlloDerm was sutured under tension to the laterally pulling oblique muscles, taking tension off the midline closure. The rectus abdominis muscles and fascia were closed in the midline under mild tension, with no change in pulmonary compliance. Skin and subcutaneous tissue were closed without tension over suction drains.

After surgery we observed no loss of pulmonary domain, no oxygen desaturation, no supplemental oxygen need, early ambulation, no infection, no dehiscence, and no ileus. Within six months, the patient remained healed until, after minor activity, she felt a tearing in the pubic area and presented with a new suprapubic hernia.

Protein and iron stores, hemoglobin level, and hematocrit were all normal. Because LEF has been reported to leech out of bone and other tissues for up to two years after stopping the drug, and because of our empirical experience with healing during the first washouts, I elected to repeat cholestyramine washout two times, and then to repair the hernia.

During surgery, I found that the first AlloDerm repair was intact and reperitonealized with no adhesions. The new tear was several inches caudal to the AlloDerm at the rectus origin from the symphysis pubis. The repopulated AlloDerm was stronger than the rectus origin from bone. I created an underlay of another piece of AlloDerm secured into the symphysis periosteum and caudal rectus fascia, and then closed the musculofascial layer over the AlloDerm. The patient healed rapidly and has remained healed for five years (Figure 2). Unfortunately, hydroxychloroquine, etanercept (Enbrel), and newer DMARDs are now used for her severe RA.

Discussion

LEF, a potent anti-inflammatory, antiproliferative, and antineoplastic drug, is one of a new generation of DMARDs for use in patients with severe RA, a group of drugs that includes etanercept, infliximab (Remicade), and adalimumab (Humira).

Normal white blood cell (WBC) function and normal fibroblast function are necessary for a normal inflammatory response and wound healing. Multiple reports show that WBC and red blood cell precursor cell lines' intra- and intercellular biochemical reactions are blocked by LEF. LEF is reported to suppress or block proliferation of multiple normal WBC lines: leukocyte phagocytic antigen-presenting cells,⁵¹ leukocyte dendritic cells,^52,53 and lymphocyte T-cells^54–57 (Figure 3). DMARDs should be considered immunosuppressive drugs, of a different class from corticosteroids.

Pyrimidine synthesis, blocked by LEF, is a key process in synovial cell production and in fibroblast collagen production. LEF therefore affects proliferation and functions of normal cell lines. LEF alters fibroblast-like synovial cell proliferation, halting progression of RA; it appears in this case to affect true fibroblasts the same way, blocking wound fibrosis and healing.

Milder adverse effects of LEF—that are not apparent clinically until the patient has a reported complication—may be treated by stopping and then restarting LEF once signs decrease.⁵⁸ However, stopping LEF is not enough to prevent suppression of wound healing after surgery. LEF leaches out of tissues for up to 2 years.⁵⁹ Surgeons should optimize conditions for wound healing, including cessation of smoking or harmful medications and the washout of suppressive DMARDs before surgery. Hernia recurrences increase with each hernia repair after the first. Recurrence is even higher in patients with associated comorbidities such as smoking or chronic obstructive pulmonary disease, massive obesity (a body mass index >35 kg/m2), and immunosuppression. This patient had no comorbidities other than RA treated with LEF. Her body mass index was 32 kg/m2, and she did not smoke or have chronic obstructive pulmonary disease. She was immunocompromised by LEF.

Any patient taking DMARDs must be made aware of potentially fatal adverse effects, give informed consent, and then be closely monitored for hepatic, gastrointestinal, hematologic, infectious, pulmonary, dermatologic, and neurologic adverse effects.^3–46 The 59th edition (2005) of the Physicians' Desk Reference provided little information on the adverse effects of LEF.⁵⁹ Serious adverse effects are typically learned from after-market reports^3–59 (Table 1). In 2010, the US Food and Drug Administration added a black-box warning to LEF about hepatic injury and failure. Box warnings of all serious adverse effects belong on data sheets of all DMARDs, similar to after-market warnings added in the past for chloramphenicol (marrow suppression) and for oral contraceptives (thromboembolism).

When a patient with RA needs surgery, how do the surgeon and rheumatologist manage medications to improve the likelihood of healing? The case I presented here is of a patient with RA whose lack of wound healing was most likely caused by the DMARD LEF. That hypothesis led to washout of LEF with cholestyramine. Clinical examination findings confirmed the effectiveness of LEF washout. Today, rapid local assays for serum LEF levels are available to confirm readiness for surgery.⁶⁰ I believe that further studies are needed both to define the effects of DMARDs on WBC cell lines, fibroblasts, and wound healing and to help guide the prudent management of DMARDs—or their washout—in these patients with complex needs who must undergo surgery.²

Disclosure Statement

The author(s) have no conflicts of interest to disclose.

Acknowledgment

Katharine O'Moore-Klopf, ELS, of KOK Edit provided editorial assistance.

References

1.    Fuerst M, Möhl H, Baumgärtel K, Rüther W. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 2006 Oct;26(12):1138–42.
2.    Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum 2007 Apr;36(5):278–86.
3.    Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 2005 Nov;25(11):1566–91.
4.    Knab J, Goos M, Dissemond J. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. J Eur Acad Dermatol Venereol 2005 Mar;19(2):243–6.
5.    Jakob A, Portsmann R, Rompel R. [Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis.] [article in German]. J Dtsch Dermatol Ges 2006 Apr;4(4):324–7.
6.    McCoy CM. Leflunomide-associated skin ulceration. Ann Pharmacother 2002 Jun;36(6):1009–11.
7.    Macdonald J, Zhong T, Lazarescu A, Gan BS, Harth M. Vasculitis associated with the use of leflunomide. J Rheumatol 2004 Oct;31(10):2076–8.
8.    Chan AT, Bradlow A, McNally J. Leflunomide induced vasculitis—a dose-response relationship. Rheumatology (Oxford) 2003 Mar;42(3):492–3.
9.    Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004 Jul–Aug;38(7–8):1206–11.
10.    Koenig AS, Abruzzo JL. Leflunomide induced fevers, thrombocytosis, and leukocytosis in a patient with relapsing polychondritis. J Rheumatol 2002 Jan;29(1):192-4.
11.    Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002 Dec 7;325(7376):1333. Erratum in: BMJ 2003 Feb 22;326(7386):432.
12.    Gottenberg JE, Venancie PY, Mariette X. Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. J Rheumatol 2002 Aug;29(8):1806–7.
13.    Fischer TW, Bauer HI, Graefe T, Barta U, Elsner P. Erythema multiforme–like drug eruption with oral involvement after intake of leflunomide. Dermatology 2003;207(4):386–9.
14.    Bandyopadhyay D. Exfoliative dermatitis induced by leflunomide therapy. J Dermatol 2003 Nov;30(11):845–6.
15.    Rivarola de Gutierrez E, Abaca H. Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy. Dermatology 2004;208(3):232–3.
16.    Schmutz JL, Barbaud A, Trechot P. [Drug-induced lichenoid eruptions]. [article in French]. Ann Dermatol Venereol 2006 Apr;133(4):409.
17.    Elias AR, Tam CC, David-Bajar KM. Subacute cutaneous lupus erythematosus associated with leflunomide. Cutis 2005 Sep;76(3):189–92.
18.    Chan SK, Hazleman BL, Burrows NP. Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 2005 Nov;30(6):724–5.
19.    Goëb V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2005 Jun;44(6):823–4.
20.    Kerr OA, Murray CS, Tidman MJ. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 2004 May;29(3):319–20.
21.    Gómez Rodriguez N, Zulaica Garate A. [Development of dermatomyositis in a woman with rheumatoid arthritis treated with leflunomide]. [Article in Spanish]. An Med Interna 2005 Jun;22(6):300–1.
22.    Vallbracht II, Popper HH, Rieber J, et al. Lethal pneumonitis under leflunomide therapy. Rheumatology (Oxford) 2005 Dec;44(12):1580–1.
23.    Martinez-Taboada VM, Rodriguez-Valverde V, Gonzalez-Vilchez F, Armijo JA. Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology (Oxford) 2004 Nov;43(11):1451–3.
24.    Ulusoy H, Bilgici A, Kuru O, Celenk C. Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report. Rheumatol Int 2005 Mar;25(2):139–42.
25.    De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003 Jul;24(7):477–82.
26.    Thomas JE, Taoka CR, Gibbs BT, Fraser SL. Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med J 2006 Jan;65(1):12–5.
27.    Hocevar A, Rozman B, Praprotnik S, et al. Leflunomide-associated tuberculosis? Rheumatology (Oxford) 2006 Feb;45(2):228–9.
28.    Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006 May;25(3):384–8.
29    Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005 Jun;32(6):1160–3.
30.    Montero JA, Ruiz-Moreno JM, Rodríguez AE, Ferrer C, Sanchis E, Alio JL. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol 2006 Mar–Apr;16(2):343–5.
31.    Lee CS, Chang, CK. Brain abscess in rheumatoid arthritis. Ann Rheum Dis 2003 Jul;62(7):689–90.
32.    Delank KS, Hansen T, Eysel P, Eckardt A. [Infections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate and Leflunomide]. [Article in German.] Z Orthop Ihre Grenzgeb 2002 Sep–Oct;140(5):555–60.
33.    Laborde F, Loeuille D, Chary-Valckenaere I. Life-threatening hypertriglyceridemia during leflunomide therapy in a patient with rheumatoid arthritis. Arthritis Rheum 2004 Oct;50(10):3398.
34.    Jahnke T, Schäfer FK, Bolte H, et al. 2005 Dr Gary J Becker Young Investigator Award: periprocedural oral administration of the leflunomide analogue FK778 inhibits neointima formation in a double-injury rat model of restenosis. J Vasc Interv Radiol 2005 Jul;16(7):903–10.
35.    Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández-Gutiérrez B, Ladero JM, Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004 Jan;36(1):82–4.
36.    Legras A, Bergemer-Fouquet AM, Jonville-Bera AP. Fatal hepatitis with leflunomide and itraconazole. Am J Med 2002 Sep;113(4):352–3.
37.    Thomasset SC, Ong SL, Large SR. Post-coronary artery bypass graft liver failure: a possible association with leflunomide. Ann Thorac Surg 2005 Feb;79(2):698–9.
38.    Verschueren P, Vandooren AK, Westhovens R. Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Clin Rheumatol 2005 Feb;24(1):87–90.
39.    Cohen JD, Jorgensen C, Sany J.
Leflunomide-induced aseptic meningitis. Joint Bone Spine 2004 May;71(3):243–5.
40.    Barak A, Morse LS, Schwab I. Leflunomide (Arava)-induced cystoid macular oedema. Rheumatology (Oxford) 2004 Feb;43(2):246–8.
41.    Metzler C, Arlt AC, Gross WL, Brandt J. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann Rheum Dis 2005 Dec;64(12):1798–800.
42.    Kopp HG, Moerike K, Kanz L, Hartmann JT. Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide. Clin Pharmacol Ther 2005 Jul;78(1):89–90. Erratum in: Clin Pharmacol Ther 2005 Sep;78(3):310.
43.    Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004 Jun;75(6):580–5.
44.    Gabelle A, Antoine JC, Hillaire-Buys D, Coudeyre E, Camu W. [Leflunomide-related severe axonal neuropathy.] [Article in French.] Rev Neurol (Paris) 2005 Nov;161(11):1106–9.
45.    Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006 Mar;36(3):162–9.
46.    Holm EA, Balslev E, Jemec GB. Vasculitis occurring during leflunomide therapy. Dermatology 2001;203(3):258–9.
47.    Scott BG, Feanny A, Hirshberg A. Early definitive closure of the open abdomen: a quiet revolution. Scand J Surg 2005;94(1):9–14.
48.    McDonald MD, Weiss III CA. Human acellular dermis for recurrent hernia. Contemp Surg 2005;61:276–80.
49.    Holton LH 3rd, Kim D, Silverman RP, Rodriguez ED, Singh N, Goldberg NH. Human acellular dermal matrix for repair of abdominal wall defects: review of clinical experience and experimental data. J Long Term Eff Med Implants 2005;15(5):547–58.
50.    Kolker AR, Brown DJ, Redstone JS, Scarpinato VM, Wallack MK. Multilayer reconstruction of abdominal wall defects with acellular dermal allograft (AlloDerm) and component separation. Ann Plast Surg 2005 Jul;55(1):41–2.
51.    Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005 Sep;52(9):2730–9.
52.    Kirsch BM, Zeyda M, Stuhlmeier K, et al. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res Ther 2005;7(3):R694–703.
53.    Zeyda M, Stuhlmeier K, Kirsch BM, Watschinger B, et al. The malononitrilamide FK778 inhibits activation of NF-kappaB in human dendritic cells. Transplant Proc 2005 May;37(4):1968–9.
54.    Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995 Jan;272(1):460–8.
55.    Part 13: disorders of the immune system, connective tissue, and joints. In: Kaspar DL, Braunwald E, Fauci AS, Hansen SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill Professional; 2005.
56.    Austen KF, Frank MM, Atkinson JP, Cantor HI, editors. Samter's immunologic diseases, vol 1. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p 53.
57.    Austen KF, Frank MM, Atkinson JP, Cantor HI, editors. Samter's immunologic diseases, vol. 1. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 55.
58.    Fleischmann R. Safety and efficacy of disease modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opin Drug Saf 2003 Jul;2(4):347–65.
59.    Physicians' desk reference. 59th ed. Montvale, NJ: Thomson PDR; 2005.
p 673–99.
60.    Sobhani K, Garrett DA, Liu DP, Rainey PM. A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients. Am J Clin Pathol 2010 Mar;133(3):454-7.